Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days
Headache
Headache Posters (7:00 AM-5:00 PM)
114

Migraine is a debilitating neurological condition, affecting 15% of Americans. A long-term safety study of rimegepant showed evidence of decreased monthly migraine days (MMD) in migraineurs treated with rimegepant 75mg.

To characterize migraine-specific quality of life (MSQ v2.1) scores and mapped EQ-5D utility values in people with migraine treated with rimegepant 75mg.

Participants were randomized into two treatment regimens: individuals with 2-14 MMDs who received rimegepant 75mg as needed (PRN), and those with 4-14 MMD at baseline who received rimegepant on a fixed every-other-day schedule (QOD+PRN). MSQ, characterized by the role function-preventive (RP), role function-restrictive (RR) and emotional function (EF) domains, was mapped to EQ-5D utilities using a validated algorithm. Outcomes were assessed at baseline and week 12 (QOD+PRN) and weeks 12, 24, 36, and 52 (PRN).

At baseline, MSQ data were available for 1,892 patients: 1,078 with 2-8 MMD (PRN), 506 with 9-14 MMD (PRN), and 308 with 4-14 MMD (QOD+PRN). For all MSQ domains and mapped utility values, outcomes improved over each study visit. At baseline, EQ-5D utilities were 0.66 for the 2-8 MMD PRN group, 0.63 for the 9-14 MMD PRN group, and 0.66 for the 4-14 MMD QOD+PRN group. At end-of-study, utilities had increased by +0.09, +0.10 and +0.12 for the three groups (p<0.001, all comparisons with baseline). Similar trends in improvement were observed across MSQ subdomains, all differences were statistically significant. Greater increase in EQ-5D was observed for patients with greater reduction in MMD.

Rimegepant 75mg, is associated with reduced MMD and improvement in MSQ domains over time, leading to increased EQ-5D utilities. While improvement was observed in all patient-groups, it was most pronounced in those with higher MMD at baseline and those taking rimegepant on a QOD+PRN schedule.

Authors/Disclosures
Karissa Johnston
PRESENTER
Karissa Johnston has nothing to disclose.
Gilbert J. L'Italien Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has stock in biohaven pharmaceuticals.
Evan Popoff Evan Popoff has nothing to disclose.
Robert Croop, MD Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has received personal compensation for serving as an employee of Pfizer Inc.. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has stock in Biohaven Ltd.. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care.
Alexandra Thiry Alexandra Thiry has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Alexandra Thiry has received stock or an ownership interest from Biohaven Pharmaceuticals.
Diego Fernandez-Vial (University of Kentucky) Linda Harris has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Linda Harris has received stock or an ownership interest from Biohaven Pharmaceuticals.
Vladimir Coric Vladimir Coric has received personal compensation for serving as an employee of Biohaven. Vladimir Coric has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Bioahven. Vladimir Coric has stock in Biohaven. Vladimir Coric has received intellectual property interests from a discovery or technology relating to health care.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.